Unipedal stance time is associated with fall outcomes in older chemotherapy-treated cancer survivors: A retrospective study.

Autor: McNeish BL; Department of Physical Medicine and Rehabilitation, University of Pittsburgh, Pittsburgh, PA, USA; Department of Neurological Sciences, Larner College of Medicine at the University of Vermont, Burlington, VT, USA. Electronic address: mcneishbl@upmc.edu., Dittus K; University of Vermont Cancer Center, Burlington, VT, USA; Department of Medicine, University of Vermont, Burlington, VT, USA. Electronic address: kim.dittus@uvmhealth.org., Mossburg J; Department of Physical Therapy, University of Vermont, Burlington, VT, USA., Krant N; Department of Neurological Sciences, Larner College of Medicine at the University of Vermont, Burlington, VT, USA. Electronic address: Nicholas.krant@med.uvm.edu., Steinharter JA; Department of Neurological Sciences, Larner College of Medicine at the University of Vermont, Burlington, VT, USA. Electronic address: john.steinharter@med.uvm.edu., Feb K; Department of Neurological Sciences, Larner College of Medicine at the University of Vermont, Burlington, VT, USA., Cote H; Department of Physical Therapy, University of Vermont, Burlington, VT, USA. Electronic address: hunter.cote@uvm.edu., Hehir MK; Department of Neurological Sciences, Larner College of Medicine at the University of Vermont, Burlington, VT, USA. Electronic address: Michael.Hehir@uvmhealth.org., Reynolds R; University of Vermont Cancer Center, Burlington, VT, USA. Electronic address: Rebecca.reynolds@uvmhealth.org., Bell SG; Department of Obstetrics and Gynecology, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: bellsg@upmc.edu., Redfern MS; Department of Bioengineering, Swanson School of Engineering, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: mredfern@pitt.edu., Rosano C; Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: RosanoC@edc.pitt.edu., Richardson JK; Department of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, MI, USA. Electronic address: jkrich@med.umich.edu., Kolb N; Department of Neurological Sciences, Larner College of Medicine at the University of Vermont, Burlington, VT, USA. Electronic address: noah.kolb@uvmhealth.org.

Publikováno v: Journal of geriatric oncology [J Geriatr Oncol] 2024 Apr; Vol. 15 (3), pp. 101667. Date of Electronic Publication: 2023 Nov 14.

Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma.

Autor: Saliby RM; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., El Zarif T; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Bakouny Z; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Department of Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Shah V; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Xie W; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts., Flippot R; Department of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France., Denize T; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Kane MH; Yale Center of Cellular and Molecular Oncology, Yale School of Medicine, New Haven, Connecticut., Madsen KN; Yale Center of Cellular and Molecular Oncology, Yale School of Medicine, New Haven, Connecticut., Ficial M; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Hirsch L; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Wei XX; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Steinharter JA; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Larner College of Medicine, University of Vermont, Burlington, Vermont., Harshman LC; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Surface Oncology, Cambridge, Massachusetts., Vaishampayan UN; University of Michigan/Karmanos Cancer Institute, Wayne State University, Detroit, Michigan., Severgnini M; Center for Immuno-Oncology Immune Assessment Laboratory at the Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., McDermott DF; Division of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts., Lee GM; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Xu W; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Van Allen EM; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., McGregor BA; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Signoretti S; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Choueiri TK; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., McKay RR; Moores Cancer Center, University of California San Diego, La Jolla, California., Braun DA; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Yale Center of Cellular and Molecular Oncology, Yale School of Medicine, New Haven, Connecticut.

Publikováno v: Cancer immunology research [Cancer Immunol Res] 2023 Aug 03; Vol. 11 (8), pp. 1114-1124.

Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study.

Autor: Bakouny Z; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, USA., Labaki C; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, USA., Bhalla S; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, USA., Schmidt AL; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, USA., Steinharter JA; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, USA., Cocco J; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, USA., Tremblay DA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, USA., Awad MM; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, USA., Kessler A; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, USA., Haddad RI; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, USA., Evans M; Department of Medicine, Icahn School of Medicine at Mount Sinai Hospital, New York, USA., Busser F; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, USA., Wotman M; Department of Medicine, Icahn School of Medicine at Mount Sinai Hospital, New York, USA., Curran CR; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, USA., Zimmerman BS; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, USA., Bouchard G; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, USA., Jun T; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, USA., Nuzzo PV; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, USA., Qin Q; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, USA., Hirsch L; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, USA., Feld J; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, USA., Kelleher KM; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, USA., Seidman D; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, USA., Huang H; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, USA., Anderson-Keightly HM; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, USA., El Zarif T; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, USA., Alaiwi SA; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, USA., Champagne C; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, USA., Rosenbloom TD; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, USA., Stewart PS; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, USA., Johnson BE; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, USA., Trinh Q; Division of Urological Surgery, Brigham and Women's Hospital, Boston, USA., Tolaney SM; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, USA., Galsky MD; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, USA., Choueiri TK; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, USA. Electronic address: toni_choueiri@dfci.harvard.edu., Doroshow DB; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, USA. Electronic address: deborah.doroshow@mssm.edu.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2022 Aug; Vol. 33 (8), pp. 836-844. Date of Electronic Publication: 2022 Jun 14.

Integrative clinical and molecular characterization of translocation renal cell carcinoma.

Autor: Bakouny Z; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Harvard Medical School, Boston, MA, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Sadagopan A; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Ravi P; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Metaferia NY; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Li J; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., AbuHammad S; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Harvard Medical School, Boston, MA, USA., Tang S; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Denize T; Harvard Medical School, Boston, MA, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Garner ER; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Gao X; Harvard Medical School, Boston, MA, USA; Department of Internal Medicine, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA., Braun DA; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Harvard Medical School, Boston, MA, USA; Yale Cancer Center / Department of Medicine, Yale School of Medicine, New Haven, CT, USA., Hirsch L; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Harvard Medical School, Boston, MA, USA., Steinharter JA; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Bouchard G; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Walton E; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., West D; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Labaki C; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Dudani S; Division of Medical Oncology/Hematology, William Osler Health System, Brampton, ON, Canada., Gan CL; Division of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada., Sethunath V; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Carvalho FLF; Division of Urology, Brigham and Women's Hospital, Boston, MA, USA., Imamovic A; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Ricker C; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Vokes NI; Department of Thoracic/Head and Neck Medical Oncology, Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX, USA., Nyman J; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Berchuck JE; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Park J; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Hirsch MS; Harvard Medical School, Boston, MA, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Haq R; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Harvard Medical School, Boston, MA, USA., Mary Lee GS; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., McGregor BA; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Chang SL; Harvard Medical School, Boston, MA, USA; Division of Urology, Brigham and Women's Hospital, Boston, MA, USA., Feldman AS; Department of Urology, Massachusetts General Hospital, Boston, MA, USA., Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., McDermott DF; Beth Israel Deaconess Medical Center, Boston, MA, USA., Heng DYC; Division of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada., Signoretti S; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Harvard Medical School, Boston, MA, USA., Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Harvard Medical School, Boston, MA, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. Electronic address: toni_choueiri@dfci.harvard.edu., Viswanathan SR; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: srinivas.viswanathan@dfci.harvard.edu.

Publikováno v: Cell reports [Cell Rep] 2022 Jan 04; Vol. 38 (1), pp. 110190.

Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma.

Autor: Bade RM; Carbone Cancer Center, University of Wisconsin-Madison, WI, USA., Schehr JL; Carbone Cancer Center, University of Wisconsin-Madison, WI, USA., Emamekhoo H; Department of Medicine, University of Wisconsin-Madison, WI, USA., Gibbs BK; Carbone Cancer Center, University of Wisconsin-Madison, WI, USA., Rodems TS; Carbone Cancer Center, University of Wisconsin-Madison, WI, USA., Mannino MC; Carbone Cancer Center, University of Wisconsin-Madison, WI, USA., Desotelle JA; Department of Medicine, University of Wisconsin-Madison, WI, USA., Heninger E; Carbone Cancer Center, University of Wisconsin-Madison, WI, USA., Stahlfeld CN; Carbone Cancer Center, University of Wisconsin-Madison, WI, USA., Sperger JM; Carbone Cancer Center, University of Wisconsin-Madison, WI, USA.; Department of Medicine, University of Wisconsin-Madison, WI, USA., Singh A; Carbone Cancer Center, University of Wisconsin-Madison, WI, USA., Wolfe SK; Carbone Cancer Center, University of Wisconsin-Madison, WI, USA., Niles DJ; Department of Biomedical Engineering, University of Wisconsin-Madison, WI, USA., Arafat W; Carbone Cancer Center, University of Wisconsin-Madison, WI, USA.; Department of Medicine, University of Wisconsin-Madison, WI, USA., Steinharter JA; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard University, Boston, MA, USA., Jason Abel E; Carbone Cancer Center, University of Wisconsin-Madison, WI, USA.; Department of Medicine, University of Wisconsin-Madison, WI, USA., Beebe DJ; Department of Biomedical Engineering, University of Wisconsin-Madison, WI, USA., Wei XX; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard University, Boston, MA, USA., McKay RR; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard University, Boston, MA, USA.; Moores Cancer Center, University of California San Diego, La Jolla, CA, USA., Choueri TK; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard University, Boston, MA, USA., Lang JM; Carbone Cancer Center, University of Wisconsin-Madison, WI, USA.; Department of Medicine, University of Wisconsin-Madison, WI, USA.

Publikováno v: Molecular oncology [Mol Oncol] 2021 Sep; Vol. 15 (9), pp. 2330-2344. Date of Electronic Publication: 2021 Mar 03.